(Q38070436)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Cutaneous toxicities of RAF inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

ChEBI release 2020-05-28

ChEBI ID

75045

author

Pablo Fernandez-Peñas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Georgina V. Long

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Rachael Anforth

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

e11-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Improving melanoma classification by integrating genetic and morphologic features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Targeting cancer with small molecule kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

BRAF targeted therapy changes the treatment paradigm in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

A phase II trial of sorafenib in metastatic melanoma with tissue correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

BRAF as therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Meta-analysis of dermatological toxicities associated with sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Ultraviolet A and photosensitivity during vemurafenib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Activation of Akt by mechanical stretching in human epidermal keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8

7 January 2021

10.1016/S1470-2045(12)70413-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference